我们应该怎样利用新抗凝剂治疗急性肺栓塞
| 作者: |
1Eckardt Jens,
2Nybo Mads
1 Department of Cardiothoracic Surgery, Odense University Hospital, Odense, Denmark 2 Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark |
| 通讯: |
Eckardt Jens
Email: ens.eckardt@ouh.regionsyddanmark.dk |
| DOI: | 10.3978/j.issn.2095-6959.2013.03.003 |
摘要
由于大多数的治疗都增加了出血并发症的风险，因此急性肺栓塞(pulmonary embolism，PE)患者的治疗成为临床医生面临的一大挑战。80%的PE患者具有可识别的诱发因素，而特发性或非触发PE在国际肺栓塞注册合作研究(International Cooperative Pulmonary Embolism Registry，ICOPER)中约占20%。PE和下肢深静脉血栓形成(deep venous thrombosis，DVT)的诱发因素相同，其中最主要的医疗机构相关诱因为大手术，因此PE是一种广为人知的术后危险并发症，大面积PE的病死率高达50%。
关键词：
急性肺栓塞
抗凝剂
New anticoagulants emerge, how can we use them for acute pulmonary embolism?
CorrespondingAuthor: JENS Eckardt Email: ens.eckardt@ouh.regionsyddanmark.dk
DOI: 10.3978/j.issn.2095-6959.2013.03.003
Abstract
A patient with acute pulmonary embolism (PE) is a challenge to the clinician because most treatments increase the risk for bleeding complications. Eighty percent of patients with PE have identifiable predisposing factors, while idiopathic or unprovoked PE was about 20% in the International Cooperative Pulmonary Embolism Registr y (ICOPER) (1). PE and deep vein thrombosis (DVT) share the same predisposing factors, where the strongest setting-related predisposing factor is major surgery and therefore, PE is a well-known and feared complication following surgery with a mortality up to 50% for massive pulmonary embolism.